LIP collaborates with Evi1 to induce AML in BMT model. (A) Kaplan-Meier analysis for the mice that had received BMT. LIP synergized with Evi1 in inducing AML. Evi1 (n = 21), LIP (n = 14), LAP (n = 6), LAP* (n = 7), Evi1/LIP (n = 16), Evi1/LAP (n = 6), Evi1/LAP* (n = 6), and Evi1/LAP*/LIP (n = 5). (B) Total cell lysates of the spleen cells and PLAT-E cells transfected with pGCDNsam-LAP*, LAP, or LIP-Kusabira Orange were immunoblotted with anti-Flag Ab (top panel, SIGMA), anti-C/EBPβ Ab (middle panel, Santa Cruz, C-19), and anti-β actin (bottom panel, Cell Signaling). The spleen cells were derived from Evi1/LIP-leukemia mice and Evi1/LIP/LAP*-leukemia mice. Mice ID numbers are shown at the top of the panels. Lane numbers are shown at the bottom of the panels. Vertical lines have been inserted to indicate repositioned gel lanes. M, size markers. (C) The Evi1-leukemic cells and the Evi1/LIP-leukemic cells showed a similar surface marker profile. Flow cytometric analysis of Evi1, LIP-, Evi1/LIP-, and the Evi1/LIP/LAP*-leukemia cells. KO indicates Kusabira Orange.